Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors

SIMPLE SUMMARY: Novel pharmacological approaches are needed to improve treatments of advanced cancers, despite the considerable benefit of immunotherapy. New drugs are searched for to complement the activity of monoclonal antibodies targeted to the PD-1/PD-L1 immune checkpoint. Here, we have identif...

Descripción completa

Detalles Bibliográficos
Autores principales: Thuru, Xavier, Magnez, Romain, El-Bouazzati, Hassiba, Vergoten, Gérard, Quesnel, Bruno, Bailly, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322126/
https://www.ncbi.nlm.nih.gov/pubmed/35884428
http://dx.doi.org/10.3390/cancers14143368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322126/
https://www.ncbi.nlm.nih.gov/pubmed/35884428
http://dx.doi.org/10.3390/cancers14143368

Ejemplares similares